Annual costs and cost per treatment completed by treatment regimen Indonesia, 1000 US$
| Year | ||||||
| 2020 | 2021 | 2022 | 2023 | 2024* | Average | |
| Indonesia | ||||||
| Current budget scenario | ||||||
| All conventional regimen | 260.1 | 493.6 | 549.8 | 570.2 | 913.3 | |
| New budget scenario | ||||||
| Conventional regimen | 260.1 | 493.6 | 406.5 | 301.8 | 456.7 | |
| BPaL | 0 | 0 | 127.2 | 159.9 | 195.0 | |
| Cost sum | 260.1 | 493.6 | 533.7 | 461.7 | 651.6 | |
| Net budget impact (%) | 0 (0) | 0 (0) | −16,1 (-3) | −108.5 (-19) | −261.7 (-29) | −128.8 (-17) |
| Cost per treatment completed | ||||||
| Conventional regimen | NA | 35.2 | 11.8 | 10.6 | 9.3 | 16.7 |
| BPaL | NA | NA | 10.2 | 6.3 | 5.0 | 7.1 |
| Kyrgyzstan | ||||||
| Current budget scenario | ||||||
| All conventional regimen | 876.7 | 1702.9 | 1902.7 | 1997.8 | 3320.7 | |
| New budget scenario | ||||||
| Conventional regimen | 876.7 | 1702.9 | 1902.7 | 1686.9 | 1688.9 | |
| BPaL | 0 | 0 | 0 | 141.6 | 400.6 | |
| Cost sum | 876.7 | 1702.9 | 1902.7 | 1828.6 | 2089.5 | |
| Net budget impact (%) | 0 (0) | 0 (0) | 0 (0) | −169.2 (-8) | −1231.2 (−37) | −700.2 (−15) |
| Cost per treatment completed | ||||||
| Conventional regimen | NA | 42.2 | 19.3 | 16.3 | 9.1 | 21.7 |
| BPaL | NA | NA | NA | 6.2 | 3.3 | 4.8 |
| Nigeria | ||||||
| Current budget scenario | ||||||
| All conventional regimen | 1620.3 | 3018.1 | 3319.9 | 3499.0 | 6125.1 | |
| New budget scenario | ||||||
| Conventional regimen | 1620.3 | 3018.1 | 2421.1 | 1365.5 | 1578.7 | |
| BPaL | 0 | 0 | 517.6 | 978.3 | 1453.6 | |
| Cost sum | 1620.3 | 3018.1 | 2938.8 | 2343.8 | 3032.3 | |
| Net budget impact (%) | 0 | 0 | −381.2 (−11) | −1155.1 (−33) | −3092.8 (−50) | −1543.0 (−32) |
| Cost per treatment completed | ||||||
| Conventional regimen | NA | 49.9 | 16.0 | 10.8 | 11.2 | 22.0 |
| BPaL | NA | NA | 9.6 | 6.9 | 5.0 | 7.2 |
BPaL, bedaquiline, pretomanid and linezolid.